secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001104659-25-075915
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel presents at-home BXCL501 market opp: patients would use in 80% of episodes
--------------------------------------------------------------------------------

- Market research shows ~3 episodes/month (36/year) per patient, vs prior 23M annual episodes estimate from claims data.
- HCPs would prescribe BXCL501 for ~16% of their bipolar/schizophrenia patients based on target product profile.
- Patients report they would use BXCL501 in 80% of at-home agitation episodes; pricing could reach $1,400+ per prescription.
- At-home setting has no approved treatments; BXCL501 targets early intervention to prevent escalation.
- SERENITY At-Home Phase 3 trial data (2,200+ episodes collected) results are upcoming.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925075915/0001104659-25-075915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925075915/tm2523088d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-075915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer